BACKGROUND AND OBJECTIVE: Recombinant FSH (r-FSH) and hMG have been used for ovulation stimulation in assisted reproductive cycles. The aim of this study was to compare the effectiveness of r-FSH and HP-hMG in assisted reproductive cycles.
METHODS: This randomized clinical trial study was done during 2005 in Babol fertility centers. After inclusion criteria, 99 persons randomly received FSH and 97 persons received HP-hMG. Two groups were matched for age, duration and cause of infertility. Data included number of follicles, number of oocytes, cycle cancellation, number of fertilization of oocytes, number of 2PN, number of ampoules, days of stimulation, number of 4 cell embryos and grade A embryos and outcomes of treatment were recorded.
FINDINGS: Number of oocytes recovered in HP-hMG (11.1) was significantly more than r-FSH (7.79) (p=0.012). There were no statistical differences in number of ampoules, days of stimulation, number of fertilization of oocytes, number of 2PN, number of 4 cell embryos and grade A embryos and pregnancy rate and outcomes of pregnancy between r-FSH and HP-hMG (p>0.05).
CONCLUSION: Recombinant FSH and HP-hMG has same advantage and complication, so type of treatment can be selected based on cost of treatment and type of administration.